NIH R01 · 2025
Upregulation of the purine biosynthetic protein phosphoribosylformylglycinamidine synthase (PFAS) promotes liver cancer cell proliferation and is prognostic for lower liver cancer survival rates. There is a fundamental gap in knowledge about how PFAS contributes to the progression of liver cancer. Exacerbating this challenge is a lack of molecular tools for the study of the function of PFAS. This underlines the critical need for the development of specific inhibitors of PFAS activity, both as probes of function and to form the basis for drug development. The long-term goal of our research program is to develop new anti-cancer therapies that regulate metabolic enzymes to extend life and…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.